Pulmatrix(PULM) - 2025 Q4 - Annual Results

Exhibit 99.1 Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results Plans to License or Monetize our Migraine and Inhalation Assets Continue Framingham, Mass., February 26, 2026 – Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announ ...